Effect of spironolactone and its main metabolite canrenone on the renin-angiotensin-aldosterone-system during long-term treatment in rats.
D000284:Administration, Oral; D000450:Aldosterone / Q000378:metabolism*; D000804:Angiotensin II / Q000378:metabolism*; D000818:Animals; D002192:Canrenone / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D008297:Male; D011245:Pregnadienes / Q000494:pharmacology*; D051381:Rats; D012083:Renin / Q000097:blood*; D013148:Spironolactone / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors; D014882:Water-Electrolyte Balance / Q000187:drug effects
D011245:Pregnadienes; D000804:Angiotensin II; D013148:Spironolactone; D000450:Aldosterone; D002192:Canrenone; D012083:Renin